Biotech Values

[DewDiligence]

MRK—In addition to the higher dose, note they are using "reformulated" raltegravir this time.

Indeed. Giving a the cumulative daily dose of a BID drug all at once is not likely to work well in terms of safety/tolerability; giving 50% more than that amount all at once is even less likely to work. Clearly, the new formulation of Isentress has a sustained-release mechanism.